Incretin Effect in People With Impaired Fasting Glucose
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 45 - 70 |
| Updated: | 10/14/2017 |
| Start Date: | January 2008 |
| End Date: | November 2008 |
Exploring the Incretin Effect in People With IFG
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of
glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to
abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the
objective of the current study. The investigators hypothesized that defects in GLP-1 may
explain the inappropriate basal EGP and diminished insulin secretion in IFG, and,
furthermore, that by increasing circulating GLP-1 levels (using a new medicine called
"sitagliptin") the investigators could reverse these defects.
glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to
abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the
objective of the current study. The investigators hypothesized that defects in GLP-1 may
explain the inappropriate basal EGP and diminished insulin secretion in IFG, and,
furthermore, that by increasing circulating GLP-1 levels (using a new medicine called
"sitagliptin") the investigators could reverse these defects.
Inclusion Criteria:
- Healthy, sedentary, non-smokers, men and women 45-70 years old Subjects were placed
into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h OGTT),
separated by one week: a control group with normal glucose tolerance (NGT; n=14;
fasting glucose <5.6 mmol/l and 2h OGTT <7.8 mmol/l), or IFG (n=10; fasting glucose
5.6-6.9 mmol/l, and 2h OGTT <7.8 mmol/l).
Exclusion Criteria:
- Subjects were excluded for: thyroid stimulating hormone <50 or >500 mU/l, fasting
triglycerides >10.3 mmol/l, creatinine >130 μmol/l, elevated liver function tests (>2X
normal), hematocrit < 38%, or WBC<3.0 x 103. Use of medications for lipid and/or
glucose lowering also excluded enrollees. Women may not have used hormone replacement
therapy in the past 1 year. Smokers. BMI <25 or >40 kg/m2. Diabetes or impaired
glucose tolerance.
We found this trial at
1
site
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
Click here to add this to my saved trials
